BACKGROUND: Obesity has been reported to be associated with coronary artery disease and other atherosclerotic diseases. Recently, evidence has accumulated indicating that intra-abdominal visceral fat accumulation contributes to atherogenesis; however, the mechanism underlying this remains to be determined. This study was undertaken to elucidate whether intra-abdominal visceral fat accumulation impairs vascular endothelial function in obese men. METHODS AND RESULTS: Thirty-eight obese men (body mass index (BMI) ! 26.0), aged 19±64 y (mean age 37.6 AE 1.8 y) and 23 age-matched non-obese subjects were examined. According to the ratio of the maximum thickness of preperitoneal fat to the minimum thickness of subcutaneous fat (Pmax/Smin) obtained by longitudinal ultrasound scanning in the subxiphoid region in obese men, we divided obese subjects into two categories; visceral (PmaxaSmin ! 1; n 23) and subcutaneous type (PmaxaSmin`1; n 15). To investigate endothelial function, we performed ultrasound measurement of the brachial artery diameter non-invasively both at rest and during reactive hyperaemia in the muscle distal to the brachial artery which causes endothelium-dependent vasodilatation. The brachial diameter change was also measured after sublingual administration of nitroglycerin, which causes endothelium-independent vasodilatation. Flow-mediated diameter (D) increase (%FMD; DDaD Â 100), in the subjects with visceral type obesity (3.09 AE 0.43%) was signi®cantly lower than those of the subjects with subcutaneous type obesity and non-obese subjects (7.90 AE 0.51%, 8.91 AE 0.44%, respectively, P`0.01). The magnitude of endothelium-independent vasodilatation by nitroglycerin was similar in all groups. On multiple regression analysis, the PmaxaSmin showed a signi®cant inverse correlation with %FMD. CONCLUSIONS: The subjects with visceral type obesity, rather than those with the subcutaneous type, are associated with impaired¯ow-mediated endothelium-dependent vasodilatation of the brachial artery.
Introduction
Obesity has long been considered to be a potent coronary risk factor. Some investigators, however, have reported that obesity is not a signi®cant contributor to coronary heart disease; it becomes a problem only when it is accompanied by other risk factors, such as hyperlipidaemia, hypertension, and diabetes. 1±4 More than 40 years ago, Vague 5 showed that upper-body obesity was a major contributor to the development of atherosclerosis. The frequency of hyperlipidaemia, diabetes, hypertension, and that of ischaemic heart disease, have been shown to be related with the body fat topography including a waist-to-hip circumference ratio (WHR). Modern techniques, such as abdominal computed tomography (CT) scanning, magnetic resonance and ultrasound imaging, 6±8 have made it possible to visualize the localization of fat in the body and have shown that upper-body obesity is connected to atherogenesis through the higher metabolic complications and hypertension. 9±11 Using CT scanning at an umbilical level, Ashwell et al 12 revealed a signi®cant correlation between intra-abdominal fat to subcutaneous fat area ratio and WHR. Upper-body obesity is now thought to be visceral type obesity. 12 To differentiate the type of obesity, we used ultrasound measurement of the thicknesses of minimum subcutaneous fat and maximum preperitoneal fat. 8 Some studies have shown an effect of obesity on the peripheral vasculature. 13, 14 Recently, Steinberg et al 15 demonstrated that in obese subjects with insulin resistance, there is an association with impaired endothelial function. However, little information is available on the mechanism underlying the higher occurrence of atherosclerosis in upper-body or visceral type obesity. We hypothesized that the endothelial function is more impaired in the subjects with visceral type obesity than in those with subcutaneous type obesity. To test this hypothesis, we measured¯ow-mediated vasodilatation, which is endothelium-dependent, 16 in obese men without overt medical problems, with special reference to the type of obesity, the visceral and subcutaneous type, because vascular endothelial dysfunction is believed to be an initial step in the development of atherosclerosis. 17 
Methods

Subjects
Thirty-eight obese men aged 37.6 AE 1.8 y (range, 19±64) were enrolled in this study. Body mass index [BMI; weight (kg)aheight (m) 2 ] was used as an indicator of body fat accumulation. Since the Working Group on Health and Obesity in the Ministry of Health and Welfare of Japan 18 reported that a BMI ! 26 is an adequate criterion to de®ne obesity in Japanese people, subjects with a BMI ! 26 were considered obese in this study. Obese subjects were recruited from medical students, hospital staff and community volunteers. Some of them had a history of an abnormal lipid pro®le or elevated blood pressure; however, they had not received any medical intervention until they were enrolled in this study. They were clinically well and were not taking any medications. Body weight of the subjects was stable for at least 12 weeks before they were enrolled in this study. Twenty-three age-matched non-obese subjects were enrolled as the control group. These subjects were recruited from the same source. These control subjects also had no signi®cant past medical history and were not on any regular medications. Each subject gave written informed consent before enrolment in this study, after thorough explanation of the study design and protocol.
Study design
Each subject made one visit to our institution. Blood sampling was performed in the morning of the examination after a 14 h overnight fast to measure serum lipid pro®le and other biochemical parameters. Serum total cholesterol and triglyceride concentrations were measured enzymatically, and serum high-density lipoprotein (HDL) cholesterol concentration was measured by the heparin-Ca 2 Ni 2 precipitation method. 19 Plasma glucose concentration was assayed by a glucose dehydrogenase method and plasma immunoreactive insulin (IRI) concentration was determined by double antibody radioimmunoassay. Haemoglobin A 1c level was measured by high performance liquid chromatography. Serum non-esteri®ed fatty acid (NEFA) concentration was measured enzymatically. 20 Measurement of¯ow-mediated and nitroglycerininduced dilatation of the brachial artery Flow-mediated dilatation (FMD) and nitroglycerin (NTG)-induced dilatation of the brachial artery were measured by an examiner who was unaware of the subjects' clinical settings, except for their physical appearance. Studies were undertaken in a quiet and temperature-controlled (22±23 C) room, according to the method described before. 21À23 The examinations were conducted by the same examiner throughout the study. The diameter of the artery was measured from high-resolution, two-dimensional ultrasound images obtained by an SSA-270A ultrasound machine (Toshiba) with a 7.5-MHz linear array transducer. Machine-operating parameters were kept constant during each study.
A subject reclined on the examination bed 15 min before the initial ultrasound scanning. The right brachial artery was scanned over a longitudinal section 3±5 cm above the right elbow. Depth and gain settings were optimized to identify the lumen-to-vessel wall interface. Blood pressure was monitored in the left arm every 2 min during the study, by an automated blood pressure recorder. An electrocardiogram monitor integrated with the ultrasound machine was also applied.
When a reasonable image was obtained, the surface of the skin was marked, and the arm was kept in the same position throughout the study. A pneumatic tourniquet placed around the forearm distal to the target artery was in¯ated to a pressure of 250 mmHg and was held for 5 min. Increased¯ow was then induced by sudden cuff de¯ation. A second scan was performed continuously for 30 s before, and 120 s after, cuff de¯ation. Then, 15 min later, a further resting scan was recorded to con®rm the vessel recovery. Sublingual NTG spray (300 mg; Myocol Spray, Toa Eiyo Co.) was then administered, and 3±5 min later, the last scan was performed.
The ultrasound images were recorded on S-VHS videotape with an SLV-RS7 videocassette recorder (Sony). The analysis of all the ultrasound images was blinded. The diameter of the brachial artery was measured from the anterior to the posterior interface, between the media and adventitia (`m-line') at a ®xed distance by electronic calipers. 24 The mean diameter was calculated from four cardiac cycles synchronized with the R-wave peaks on the electrocardiogram. All measurements were made at end-diastole, to avoid possible errors resulting from variable arterial compliance. 25 Maximal vasodilatation was observed 45±60 s after the cuff release. 21, 23 The diameter change, caused by¯ow-mediated vasodilatation, was expressed as the percent change relative to that at the initial resting scan (%FMD). The diameter change caused by NTG was expressed in the same way as the percent change relative to that at the recovery scan (%NTG). The pulse wave velocity pro®le of blood¯ow was simultaneously recorded. Mean¯ow velocity was calculated by measuring the area under this velocity pro®le curve. Blood¯ow (mLamin) was then calculated by multiplying the cross-sectional area of the brachial artery based on the diameter and the mean¯ow velocity.
Changes in diameter of 0.1± 0.2 mm can be detected accurately with this method. 22, 26, 27 The variability of the ultrasound measurements was studied for both %FMD and %NTG by repeated measurements from the same video recordings in six subjects. 23 The
Flow-mediated vasodilatation in obesity M Hashimoto et al coef®cient of variation for measurements of %FMD was 5.84 AE 0.25%. The coef®cient of variation for measurements of %NTG was 3.97 AE 0.24%. To evaluate the reproducibility of this ultrasound examination, the examinations were repeated ®ve times in one month for eight male subjects. 23 The coef®cient of variation of %FMD during one month was 9.77 AE 0.82%. Similarly, the coef®cient of variation of %NTG during one month was 7.24 AE 0.49%.
Measurement of abdominal fat layers
Abdominal ultrasound measurement of fat layers was performed according to the method of Suzuki et al. 8 This measurement was applied only to the obese subjects to differentiate the type of obesity. While subjects were in the supine position, a linear-array ultrasound probe (3.75 MHz), which was part of the same ultrasound machine, was applied perpendicularly to the surface of the skin on the abdomen. The longitudinal scanning was performed from the xiphoid process to the umbilicus along the linea alba. Scanning was obtained at the optimal position, and the surface of the liver was kept almost parallel to the skin by the subjects holding their breath. The thicknesses of minimum subcutaneous fat (Smin) and maximum preperitoneal fat (Pmax) were measured directly from the B-mode screen with electronic calipers, and PmaxaSmin was calculated. PmaxaSmin is signi®cantly correlated with VaS ratio obtained by CT scanning. 8 The mean PmaxaSmin by ultrasound scanning was 1.0. Therefore, according to the previous report, 8 we divided obesity into two categories, the visceral (PmaxaSmin ! 1) and subcutaneous (PmaxaSmin`1) groups depending on PmaxaSmin. The measurement was performed by the same examiner who studied the brachial artery. The coef®-cient of variation for the ®ve measurements of PmaxaSmin in each of ®ve different subjects was 2.14 AE 0.02%. Typical scans of the subcutaneous and visceral type obesity are shown in Figure 1 .
The same measurement was also attempted in the non-obese subjects. However, since the surface of the liver was not parallel to the skin anatomically and the angulation of the liver was sharp in some subjects, we decided not to measure Smin and Pmax in the nonobese subjects, because the measurements appeared inaccurate.
Statistical analysis
All data in the text, tables and ®gures are expressed as mean AE s.e.m. An analysis of variance followed by Newman-Keuls test was performed to isolate the differences between groups. The number of smokers in the three groups were analyzed by chi-square test. Simple correlations of %FMD with various factors were performed. Standardized regression coef®cients of %FMD in relation to various factors were assessed by multiple regression analysis. Similar analysis was also performed with NTG-induced dilatation. A value of P`0.05 was considered statistically signi®cant.
Results
Clinical characteristics
In 38 obese subjects, 15 were classi®ed as subcutaneous and 23 as visceral type obesity. Clinical data of obese and non-obese subjects are presented in Table 1 . BMI in subjects with both subcutaneous and visceral type obesity were signi®cantly greater than that of non-obese subjects. Systolic blood pressure was signi®cantly higher in the obese subjects than in the non-obese subjects. However, there were no signi®-cant differences in BMI and systolic blood pressure between the subjects with subcutaneous obesity and subjects with visceral type obesity. Table 2 shows metabolic characteristics of the subjects. Serum total cholesterol and triglyceride concentrations were signi®cantly elevated in the subjects with visceral type obesity compared with those in subjects with subcutaneous type obesity and nonobese subjects. The serum HDL-cholesterol concentrations in both obese subjects was signi®cantly lower than that of non-obese subjects. Fasting plasma glucose, insulin and haemoglobin A 1c values were not signi®cantly different among the three groups. Serum NEFA concentration was signi®cantly higher in the subjects with the subcutaneous and visceral type obesity than in the non-obese subjects.
FMD and NTG-induced dilatation of the brachial artery
As shown in Table 3 , there were no signi®cant differences in the diameter at rest and magnitude of reactive hyperaemia produced by cuff in¯ation and release among the three groups. As shown in Figure 2 , %FMD in the subjects with visceral type obesity (3.10 AE 0.43%) was signi®cantly lower than those of subjects with subcutaneous type obesity and non-obese subjects (7.90 AE 0.51% and 8.91 AE 0.44%, respectively). %NTG was similar in all groups. Figure 1 Typical ultrasound scans of subjects with subcutaneous and visceral type obesity. Arrows indicate the actual measurement sites. A; a subject with thickened subcutaneous fat compared to preperitoneal fat. Maximum thickness of preperitoneal fat (Pmax) 11.9 mm, minimum thickness of subcutaneous fat (Smin) 17.7 mm, Pmax/Smin 0.67. B; a subject with thickened preperitoneal fat compared to subcutaneous fat. Pmax 14.2 mm, Smin 7.5 mm, Pmax/Smin 1.9. S subcutaneous fat layer, P preperitoneal fat layer.
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To investigate the relationship between %FMD and other factors including PmaxaSmin, the following analysis of the 38 obese subjects was completed. As shown in Figure 3 , %FMD was inversely related to PmaxaSmin on simple regression analysis (r 7 0.70, P`0.0001). %FMD was inversely correlated with Pmax (r 7 0.49, P`0.01) and positively correlated with Smin (r 0.45, P`0.01). Data are expressed as mean AE s.e.m. * P`0.05 vs non-obese subjects; ** P`0.01 vs non-obese subjects; *** P`0.05 vs subcutaneous type obesity; **** P`0.01 vs subcutaneous type obesity. HDL high-density lipoprotein. Figure 2 Comparison of¯ow-mediated dilatation (%FMD) and nitroglycerin-induced dilatation (%NTG) in non-obese control subjects, subjects with subcutaneous and visceral type obesity. Data are expressed as mean AE s.e.m. C non-obese control subjects; S subjects with subcutaneous type obesity; V subjects with visceral type obesity. n number of subjects. NS not signi®cant, ** P`0.01.
The simple correlation coef®cients of %FMD with PmaxaSmin (r 7 0.70, P`0.0001), serum total cholesterol (r 7 0.41, P`0.05), and triglyceride (r 7 0.37, P`0.05) levels showed signi®cant negative correlations with %FMD, respectively. On multiple regression analysis, only PmaxaSmin was found to be signi®cantly correlated with %FMD (P`0.0001). When hypercholesterolaemic subjects (serum total cholesterol levels b240 mgadl, 6.21 mmolal) were excluded, we still found a signi®cant difference in %FMD (3.14 AE 0.52% visceral type obesity, n 13; 7.97 AE 0.54% subcutaneous type obesity, n 10 and 8.91 AE 0.44% non-obese subjects, n 23; P`0.01). When hypertriglyceridaemic subjects (serum triglyceride level b150 mgadl, 1.69 mmolal) were excluded, we also found a signi®cant difference in %FMD (3.81 AE 0.46% visceral type obesity, n 9; 8.68 AE 0.93% subcutaneous type obesity, n 7 and 8.88 AE 0.48% non-obese subjects, n 21; P`0.01). Furthermore, when smokers were excluded from the study, we obtained similar differences in %FMD (3.67 AE 0.51% visceral type obesity, n 13; 7.81 AE 0.74% subcutaneous type obesity, n 10; and 8.85 AE 0.45% non-obese subjects, n 18; P`0.01).
On multiple regression analysis, %NTG was inversely related to vessel size (P`0.01) but was not signi®cantly related to age, BMI, mean blood pressure, PmaxaSmin, serum total cholesterol and triglyceride levels.
Discussion
To investigate the mechanism underlying the atherogenic property of obesity, we examined the endothelium-dependent¯ow-mediated vasodilatation of the brachial artery non-invasively in obese subjects with special reference to body fat topography. Fujioka et al 9 de®ned visceral-type obesity as visceral to subcutaneous area (VaS ratio) obtained by CT scanning image at the level of the umbilicus over 0.4. Suzuki et al 8 reported that Smin correlated well with the subcutaneous fat area by CT scanning and Pmax was well correlated with the visceral fat area. Preperitoneal fat of which amount they measured as Pmax has been known to share common properties with visceral fat. 8 They also reported that PmaxaSmin was signi®cantly correlated with the VaS ratio obtained by CT scanning. 8 Therefore, depending on PmaxaSmin, we Figure 3 Simple correlation of¯ow-mediated dilatation (%FMD) with ratio of the maximum thickness of preperitoneal fat to the minimum thickness of subcutaneous fat (Pmax/Smin) (A), Pmax (B) and Smin (C). Data are expressed as mean AE s.e.m. * P`0.01 vs non-obese subjects. ** P`0.01 vs subcutaneous type obesity.
Flow-mediated vasodilatation in obesity M Hashimoto et al divided obesity into two categories, the visceral (PmaxaSmin ! 1) and subcutaneous (PmaxaSmin`1) groups as de®ned by Suzuki et al. 8 We found that thē ow-mediated vasodilatation was signi®cantly impaired in the subjects with visceral type obesity, compared to that in the subjects with subcutaneous type obesity. Surprisingly, the¯ow-mediated vasodilatation in the subjects with subcutaneous type obesity was similar to that in non-obese control subjects. Moreover, PmaxaSmin and Pmax, both of which were indices of visceral fat accumulation, showed a signi®cant negative correlation with¯ow-mediated vasodilatation. The impairment of¯ow-mediated vasodilatation in the subjects with visceral type obesity was not due to the change in the dilatory property of the brachial artery, because the endothelium-independent vasodilatation induced by nitroglycerin was similar in all groups. These results clearly indicate that the impairment of endotheliumdependent vasodilatation is signi®cantly correlated with the magnitude of visceral fat accumulation.
A number of reports have demonstrated that visceral fat accumulation is closely associated with metabolic disorders such as insulin resistance, glucose intolerance and hyperlipidaemia. 28, 29 It is also reported that chronic hyperglycaemia impairs endothelial function and insulin sensitivity in patients with insulin-dependent diabetes mellitus. 30 Therefore, the impairment of endothelium-dependent vasodilatation may be due to these metabolic disorders. Indeed, we found that subjects with visceral type obesity showed a signi®cantly altered serum lipid pro®le including higher serum total cholesterol and triglyceride levels. Celermajer et al 21 reported that children with familial hypercholesterolaemia showed impaired ow-mediated vasodilatation. However, on multiple regression analysis, only PmaxaSmin was found to be independently correlated with the impairment of endothelial dysfunction. Furthermore, when we excluded subjects with hypercholesterolaemia and hypertriglyceridaemia, we still found a signi®cant difference in¯ow-mediated vasodilatation among the three groups. Thus, the¯ow-mediated vasodilatation is impaired by a mechanism independent of these metabolic disorders.
Insulin resistance may play an improvement role in atherogenesis in visceral type obesity. 9, 11, 31 In our study, no signi®cant differences in plasma fasting glucose, IRI and haemoglobin A 1c levels were found among the three groups. Since we did not perform the oral glucose tolerance test with plasma IRI measurement or other insulin sensitivity tests, it is dif®cult to evaluate the role of insulin resistance in the impairment of¯ow-mediated vasodilatation. The possibility that insulin resistance plays a role in the endothelial dysfunction should not be neglected, and needs further clari®cation.
Increased nitric oxide (NO) production, induced by the increased¯ow, has been proposed as the main mechanism underlying the¯ow-mediated vasodilatation induced by reactive hyperaemia. 32±34 Some kinds of NO synthase inhibitors have been demonstrated to inhibit endothelium-dependent vasodilatation induced by reactive hyperaemia in the human radial artery 35 and in the human coronary artery. 32±34 However, the effect of visceral type obesity on NO synthesis in vascular endothelial cells is unknown. Moreover, the mechanism responsible for impaired endothelial function in visceral fat accumulation is not fully understood. Evidence has accumulated that adipocytes synthesize some kinds of vasoactive substances such as tumor necrosis factor (TNF)-a, 36 plasminogen activator inhibitor (PAI)-1 31, 37, 38 and von Willebrand factor. 39 These may be involved in the mechanism of endothelial dysfunction. 15 TNF-a has been demonstrated to downregulate an endothelial NO synthase mRNA. 40 It is also possible that TNF-a locally generates secondary mediators which affect insulin response at distant sites. 36 As for PAI-1, it was reported to be negatively correlated with the magnitude of insulin sensitivity measured with the euglycaemic clamp technique. 37 In any case, further study is necessary to investigate the causative substances responsible for endothelial dysfunction in the subjects with visceral fat accumulation.
Recently, Steinberg et al 15 demonstrated that obesityainsulin resistance is associated with endothelial dysfunction. Since Steinberg et al 15 did not investigate the body fat topography, it is of interest to see the body fat distribution and endothelial function in the patients studied. We assume that in their study, most of the obese subjects and subjects with non-insulin dependent diabetes mellitus have visceral fat accumulation in their abdomen. Their ®nding is, at least in part, compatible with our ®nding in this study concerning endothelial dysfunction in obesity. Therefore, it is probable that insulin resistance is involved in the mechanism of impaired endothelial function in the visceral type obesity. Again, this remains to be determined.
Conclusion
The present study demonstrates that the endotheliumdependent vasodilatation is impaired in subjects with visceral type obesity, but not with subcutaneous type obesity. These results suggest that visceral fat accumulation, rather than obesity itself, may play an important role in the pathogenesis of atherosclerosis in obese subjects.
